JPMorgan Chase & Co. Begins Coverage on Zealand Pharma A/S (OTCMKTS:ZLDPF)

Investment analysts at JPMorgan Chase & Co. assumed coverage on shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The brokerage set an “overweight” rating on the stock.

Zealand Pharma A/S Stock Performance

OTCMKTS ZLDPF opened at $121.72 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.57 and a quick ratio of 35.57. Zealand Pharma A/S has a 1-year low of $40.40 and a 1-year high of $141.74. The business has a 50 day simple moving average of $122.70 and a two-hundred day simple moving average of $115.74. The stock has a market capitalization of $6.27 billion, a PE ratio of -50.09 and a beta of 0.96.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, August 15th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.06). The business had revenue of $4.93 million during the quarter, compared to analysts’ expectations of $0.50 million. Zealand Pharma A/S had a negative net margin of 191.92% and a negative return on equity of 18.17%. On average, research analysts predict that Zealand Pharma A/S will post -2.48 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.